[go: up one dir, main page]

WO2009053733A3 - Novel crystalline forms - Google Patents

Novel crystalline forms Download PDF

Info

Publication number
WO2009053733A3
WO2009053733A3 PCT/GB2008/050967 GB2008050967W WO2009053733A3 WO 2009053733 A3 WO2009053733 A3 WO 2009053733A3 GB 2008050967 W GB2008050967 W GB 2008050967W WO 2009053733 A3 WO2009053733 A3 WO 2009053733A3
Authority
WO
WIPO (PCT)
Prior art keywords
crystalline forms
novel crystalline
novel
relates
tegaserod
Prior art date
Application number
PCT/GB2008/050967
Other languages
French (fr)
Other versions
WO2009053733A2 (en
Inventor
Abhay Gaitonde
Bindu Manojkumar
Sandeep Sonawane
Dattatrey Kokane
Sinderpal Tank
Vikas Padalkar
Original Assignee
Generics [Uk] Limited
Mylan Development Centre Private Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics [Uk] Limited, Mylan Development Centre Private Limited filed Critical Generics [Uk] Limited
Publication of WO2009053733A2 publication Critical patent/WO2009053733A2/en
Publication of WO2009053733A3 publication Critical patent/WO2009053733A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to novel crystalline forms of the succinate salt of tegaserod, and to processes for the preparation of these novel crystalline forms. The invention also relates to pharmaceutical compositions containing these novel polymorphs, and to uses of said compositions to provide methods of treating patients suffering from gastrointestinal disorders.
PCT/GB2008/050967 2007-10-24 2008-10-18 Novel crystalline forms WO2009053733A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2105/MUM/2007 2007-10-24
IN2105MU2007 2007-10-24

Publications (2)

Publication Number Publication Date
WO2009053733A2 WO2009053733A2 (en) 2009-04-30
WO2009053733A3 true WO2009053733A3 (en) 2009-09-03

Family

ID=40210703

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/050967 WO2009053733A2 (en) 2007-10-24 2008-10-18 Novel crystalline forms

Country Status (1)

Country Link
WO (1) WO2009053733A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod
WO2008149154A2 (en) * 2007-06-05 2008-12-11 Generics [Uk] Limited Tegaserod succinate and polymorphic forms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0297651B1 (en) 1987-06-29 1993-11-03 Duphar International Research B.V Anellated indole derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
GB9721139D0 (en) 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006116953A1 (en) * 2005-05-02 2006-11-09 Zentiva, A.S. A method for the preparation of tegaserod and slected salts thereof
EP1939176A1 (en) * 2006-12-22 2008-07-02 Novartis AG Salts of Tegaserod
WO2008149154A2 (en) * 2007-06-05 2008-12-11 Generics [Uk] Limited Tegaserod succinate and polymorphic forms

Also Published As

Publication number Publication date
WO2009053733A2 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
WO2008132139A3 (en) New heterocyclic derivatives useful for the treatment of cns disorders
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
WO2008152099A3 (en) Aryl/hetarylamides as modulators of the ep2 receptor
WO2009064460A3 (en) Gastrointestinal delivery systems
EP2305640A3 (en) Substituted diphenyl-ethers, -amines, -sulfides and -methanes for the treatment of respiratory diseases
WO2007052023A3 (en) Novel compounds
WO2009104021A3 (en) Novel polymorphs and processes for their preparation
WO2009111700A3 (en) Oxadiazoanthracene compounds for the treatment of diabetes
WO2011082266A3 (en) Substituted heterocyclic compounds
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2009067686A3 (en) Sunitinib hemi-l-malate, polymorphs and preparation thereof, polymorphs of racemic sunitinib malate, compositins containing sunitinib base and malic acid and preparation thereof
WO2010055082A3 (en) New crystal form of sunitinib malate
WO2008152093A3 (en) Diaminopyrimidines as modulators of the ep2 receptor
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
UA96447C2 (en) Polymorph forms of (2s)-(4e)-n-methyl-5- (3-isopropoxypyridin) yl]-4-penten-2-amine for the treatment of central nervous system disorders
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2010049449A3 (en) Novel salts of sunitinib
WO2008088779A3 (en) Solid state forms of 5-azacytidine and processes for preparation thereof
WO2007042544A3 (en) Imidazole derivatives and their use for modulating the gabaa receptor complex
WO2006058869A3 (en) Substituted pteridines for treating inflammatory diseases
WO2009109501A3 (en) Ocular pharmaceutical compositions
WO2011022393A3 (en) Phosphatidylcholine transfer protein inhibitors
WO2008033935A3 (en) Vinorelbine derivatives
WO2006056607A8 (en) Substituted pteridines for treating inflammatory diseases
AU2009235968A8 (en) Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08806781

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08806781

Country of ref document: EP

Kind code of ref document: A2